Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease

There is a growing body of evidence from epidemiologic, clinical, and laboratory data that indicates that elevated triglyceride levels are an independent risk factor for cardiovascular disease. Identification and quantification of atherogenic lipoproteins in patients with hypertriglyceridemia are im...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 1999-05, Vol.83 (9), p.3-12
Main Author: Brewer, H.Bryan
Format: Article
Language:English
Subjects:
Apolipoproteins - metabolism
Biological and medical sciences
Cardiovascular disease
Cardiovascular Diseases - etiology
Cholesterol, LDL - blood
Cholesterol, LDL - metabolism
Disorders of blood lipids. Hyperlipoproteinemia
Fatty acids
Female
Humans
Hypertriglyceridemia - complications
Hypertriglyceridemia - metabolism
Lipids
Lipoproteins - blood
Lipoproteins - metabolism
Male
Medical sciences
Metabolic diseases
Plasma
Proteins
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a growing body of evidence from epidemiologic, clinical, and laboratory data that indicates that elevated triglyceride levels are an independent risk factor for cardiovascular disease. Identification and quantification of atherogenic lipoproteins in patients with hypertriglyceridemia are important steps in the prevention of cardiovascular disease. Increased levels of apoC-III, apoC-I, or apoA-II on the apoB-containing lipoproteins may alter lipoprotein metabolism and result in the accumulation of atherogenic remnants. Hypertriglyceridemic patients at risk for cardiovascular disease often develop a lipoprotein profile characterized by elevated triglyceride, dense LDL, and low HDL cholesterol. Understanding that each of these factors contributes separately to the patient’s risk of cardiovascular disease can help physicians provide patients with more effective risk-reduction programs for cardiovascular disease.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(99)00308-2